Core Insights - Plus Therapeutics, Inc. has appointed Russell Bradley as President and General Manager of its subsidiary CNSide Diagnostics, LLC, aiming to enhance its operations in the diagnostic landscape for CNS cancers [2][3] - The company has also appointed Dr. Marc Hedrick, Mr. Rick Hawkins, and Mr. Russell Bradley to the CNSide Board of Directors, while Dr. Jonathan Stein has been named Medical Director [2][3] Company Developments - Russell Bradley brings over 30 years of leadership experience in diagnostics and life sciences, having held senior roles at Abbott Laboratories, Luminex Corporation, and Beckman Coulter, and is expected to make an immediate impact on CNSide [3] - The immediate priority for CNSide Diagnostics is to support early access and initial launch plans in the U.S. for its diagnostic tools targeting leptomeningeal disease [4] Product and Market Focus - CNSide Diagnostics develops proprietary laboratory-developed tests designed to identify tumor cells that have metastasized to the central nervous system, particularly for patients with carcinomas and melanomas [6] - The CNSide platform includes four laboratory-developed tests for treatment selection and monitoring of patients with leptomeningeal metastases, utilizing both cellular and molecular assays [7][8] - The CNSide CSF tumor cell enumeration LDT is currently being used in the ReSPECT-LM trial and is expected to be commercially available in 2025 [8] Industry Context - Leptomeningeal metastases (LM) is a rare but serious complication of cancer, affecting approximately 5% of cancer patients, with a particularly high incidence in breast cancer patients [5] - There are currently no FDA-approved therapies specifically for LM patients, highlighting a significant unmet medical need in the market [5]
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary